EFElena S. Fedenko

Elena S. Fedenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena S. Fedenko has a total of 321 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First Russian recombinant allergy vaccine: a brief review of research results

    by Elisyutina Elisyutina, Елисютина Ольга Гурьевна, Natalya I. Ilina, Ильина Наталья Ивановна, Elena S. Fedenko, Феденко Елена Сергеевна, Evgeniia V. Nazarova, Назарова Евгения Валерьевна, Oksana M. Kurbacheva, Курбачева Оксана Михайловна, et al.

    Allergen-specific immunotherapy is a form of etiological treatment for patients with immunoglobulin E mediated allergic diseases. Allergen-specific immunotherapy is based on the administration of causative allergens in order to induce immunological tolerance to it. The main advantages of allergen-specific immunotherapy over all other available treatments for allergy are that it induces long-lasting protection and prevents the progression of the disease to more severe manifestations. This article reviews the results of studies on a promising allergy vaccine developed for allergen-specific immunotherapy in birch pollen allergy.

  • Spectrum of IgE sensitization to allergen components in adults with atopic dermatitis: experience with a domestically developed allergen microarray

    by Evgeniy V. Smolnikov, Смольников Евгений Валентинович, Olga G. Elisyutina, Елисютина Ольга Гурьевна, Victoria O. Sklyarova, Склярова Виктория Олеговна, Valeriia S. Iuzhaninova, Южанинова Валерия Сергеевна, Elena S. Fedenko, Феденко Елена Сергеевна

    BACKGROUND: Molecular allergy diagnostics enables characterization of immunoglobulin E sensitization to individual allergen components. Data on the use of domestically developed multiplex platforms in adults with atopic dermatitis remain limited. AIM: To characterize the spectrum of immunoglobulin E sensitization to allergen components and assess its associations with clinical and laboratory characteristics in adults with atopic dermatitis using a domestically developed allergen microarray. METHODS: This single-center retrospective cross-sectional study included 38 adults with atopic dermatitis examined in 2024–2025. Serum bank samples and medical records were analyzed. Allergen-specific immunoglobulin E was measured using the ProAllergy multiplex allergen microarray, comprising 36 allergen extracts and 64 molecular allergen components. A specific immunoglobulin E result ≥0.35 kU/L was considered positive. Associations among atopic dermatitis severity, total immunoglobulin E level, and the number of components with positive specific immunoglobulin E were assessed, along with differences in these parameters between patients with and without asthma. RESULTS: Specific immunoglobulin E to Bet v 1 was detected most frequently, in 30 patients (78.9 %), followed by Fel d 1 in 16 (42.1 %), Phl p 1 in 12 (31.6 %), and Art v 1 in 11 (28.9 %). Among food allergen components, specific immunoglobulin E to PR-10 family proteins was detected most frequently: Dau с 1 in 15 patients (39.5 %), Cor a 1.04 in 14 (36.8 %), Api g 1 in 11 (28.9 %), and Fra a 1 in 7 (18.4 %). The SCORAD index correlated with the number of components with positive specific immunoglobulin E (rS = 0.34; p = 0.034) and with total immunoglobulin E level (rS = 0.52; p 0.001). When total immunoglobulin E was taken into account, the partial correlation between the SCORAD index and the number of components with positive specific immunoglobulin E was not statistically significant (rS = 0.04; p = 0.830). The number of components with positive specific immunoglobulin E was higher in patients with AD and concomitant asthma than in those without asthma: 13 [6; 19] versus 4 [2; 7] (padj = 0.009). CONCLUSION: Adults with atopic dermatitis showed a heterogeneous immunoglobulin E sensitization profile, with predominance of specific immunoglobulin E to Bet v 1 and homologous PR-10 family proteins. The number of components with positive specific immunoglobulin E was associated with total immunoglobulin E level and the presence of asthma. After accounting for total immunoglobulin E, no statistically significant association between this parameter and the SCORAD index was observed.

  • Open Access

    Comorbidity profiles in adults with different rhinitis phenotypes: a comparative analysis

    by Linda U. Amzaeva, Амзаева Линда Усмановна, Olga G. Elisyutina, Елисютина Ольга Гурьевна, Evgeniy V. Smolnikov, Смольников Евгений Валентинович, Alla O. Litovkina, Литовкина Алла Олеговна, Elena S. Fedenko, Феденко Елена Сергеевна

    BACKGROUND: The comorbidity profile of local allergic rhinitis remains insufficiently studied, and data from direct comparisons of local allergic rhinitis with allergic rhinitis and non-allergic rhinitis within a single cohort are limited. AIM: To compare the patterns and prevalence of comorbid conditions in adult patients with allergic rhinitis, local allergic rhinitis, and non-allergic rhinitis. METHODS: A single-center retrospective secondary analysis was performed using data from a cohort of adults with chronic rhinitis assembled in 2023–2024 based on clinical and allergy evaluation. Allergic rhinitis was diagnosed when immunoglobulin E mediated sensitization to clinically relevant aeroallergens was identified. In the absence of such sensitization, local allergic rhinitis and non-allergic rhinitis were differentiated based on positive and negative nasal allergen challenge results, respectively. Data from 2,078 patients were analyzed, including 1,989 with allergic rhinitis, 14 with local allergic rhinitis, and 75 with non-allergic rhinitis. The frequencies of comorbid conditions were compared, and the association between the number of type 2 inflammation–associated conditions and membership in the local allergic rhinitis group versus the non-allergic rhinitis group was assessed with adjustment for age. RESULTS: Compared with non-allergic rhinitis, allergic rhinitis was more frequently associated with bronchial asthma (35.9 % vs 12.0 %; odds ratio 3.92; adjusted p 0.001), conjunctivitis (50.4 % vs 29.3 %; odds ratio 2.42; adjusted p = 0.001), and food allergy (12.8 % vs 0 %; adjusted p 0.001). Atopic dermatitis was more frequent in local allergic rhinitis than in non-allergic rhinitis (35.7 % vs 6.7 %; odds ratio 7.78; adjusted p = 0.023). Compared with allergic rhinitis, non-allergic rhinitis was more frequently associated with chronic bronchitis (odds ratio 3.76; adjusted p 0.001), chronic obstructive pulmonary disease (odds ratio 10.21; adjusted p 0.001), and gastroesophageal reflux disease (odds ratio 2.66; adjusted p = 0.002). In the age-adjusted model, a higher number of conditions associated with type 2 inflammation was associated with belonging to the local allergic rhinitis group rather than the non-allergic rhinitis group (odds ratio 23.0; 95 % confidence interval 4.5–118.5; p 0.001). CONCLUSION: Comorbidity profiles differed among allergic rhinitis, local allergic rhinitis, and non-allergic rhinitis. Allergic rhinitis was more frequently associated with bronchial asthma, conjunctivitis, and food allergy; local allergic rhinitis with atopic dermatitis; and non-allergic rhinitis with chronic bronchitis, chronic obstructive pulmonary disease, and gastroesophageal reflux disease. Comorbidity profiles may complement clinical phenotype assessment but cannot serve as an independent basis for diagnosing a rhinitis phenotype. Findings concerning local allergic rhinitis require confirmation in larger samples.

  • Open Access

    Long-term dupilumab therapy in atopic dermatitis and prurigo nodularis: clinical cases

    by Elena S. Fedenko, Феденко Елена Сергеевна, Evgeniy V. Smolnikov, Смольников Евгений Валентинович, Victoria O. Sklyarova, Склярова Виктория Олеговна, Valeriia S. Iuzhaninova, Южанинова Валерия Сергеевна, Ivan A. Sergeev, Сергеев Иван Алексеевич, et al.

    Atopic dermatitis and prurigo nodularis are chronic inflammatory skin diseases characterized by intense pruritus, skin lesions that differ in their morphology and distribution, and a substantial impact on patients’ quality of life. Type 2 inflammation, mediated in part by interleukins 4 and 13, plays an important role in the pathogenesis of both diseases. Dupilumab, which blocks signaling pathways mediated by these cytokines through binding to the α-subunit of the interleukin-4 receptor, is used as targeted therapy for atopic dermatitis and prurigo nodularis. Considerable experience with long-term dupilumab therapy has accumulated in atopic dermatitis, whereas information on prolonged treatment of prurigo nodularis is based predominantly on real-world studies. We present two clinical cases of dupilumab therapy in female patients with atopic dermatitis and prurigo nodularis. In both cases, treatment was associated with a substantial reduction in the severity of skin manifestations and pruritus, improvement in quality of life, and a reduced need for concomitant therapy. The achieved clinical response was sustained throughout the follow-up period. Dupilumab therapy was not interrupted during the entire follow-up period, and no adverse events were recorded. These clinical observations add to the available evidence on the long-term use of dupilumab in atopic dermatitis and prurigo nodularis.

  • Open Access

    Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

    by Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, et al.

    Background: We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, AB ‐ PreS , consisting of allergen‐derived peptides fused to the hepatitis B virus ( HBV )‐derived PreS surface protein as immunological carrier. Objective: To investigate in a clinical study the usefulness of the AB ‐ PreS vaccine, termed GNR ‐127, for allergen‐specific immunotherapy of birch pollen allergy. Methods: Stage 1 of the study, an open‐label Phase I study, determined among three doses (20 μg: n = 6; 40 μg: n = 6; 80 μg: n = 6) administered as Aluminum‐hydroxide‐adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: n = 45; 40 μg: n = 43; 80 μg: n = 44) received in a single‐blind, placebo‐controlled Phase II study monthly up to five pre‐seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology ( EAACI ) guidelines; allergen‐specific antibodies and basophil sensitivity were determined by ELISA and basophil activation testing, respectively. Results: A dose‐dependent reduction of the combined symptom medication score ( CSMS ) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1‐specific IgG (median 20‐fold increase) and a blunting of the seasonally boosted IgE response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses. Conclusion: A pre‐seasonal course of 5 monthly injections of GNR ‐127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1‐specific IgG response, paving the road for a Phase III efficacy study. Trial Registration: ClinicalTrials.gov (Identifier: NCT07155499)


  • Open Access

    Current Guidelines for the Management of Patients with Food Allergy

    by Leyla S. Namazova-Baranova, Aleksander A. Baranov, Anna A. Alekseeva, Eduard T. Ambarchyan, Natalya G. Astafyeva, Irina V. Vahlova, Anita R. Denisova, Olga G. Elisyutina, Marika I. Ivardava, Natalya I. Ilyina, et al.

    This article summarizes current epidemiological, etiological, and clinical aspects of food allergy in children. Evidence-based approaches to diagnosis (including differential diagnosis), treatment, and prevention are presented. Practical management algorithms for patients are outlined, developed on the basis of current scientific literature and recent clinical data on food allergy.

  • Microbial skin colonization in patients with atopic dermatitis: Association with immunological parameters and clinical disease severity

    by K. K. Nosyreva, O. G. Elisyutina, E. V. Smolnikov, D. P. Shut, E. S. Fedenko, M. N. Boldyreva

    Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by impaired epidermal barrier function, immune dysregulation, and altered microbial ecology. Over recent decades, there has been a steady increase in its prevalence, making AD one of the most pressing issues in dermatology. The aim of this study was to comprehensively assess bacterial skin colonization in patients with AD using real-time quantitative PCR and to analyze its relationship with clinical and immunological parameters of the disease. A prospective study included 110 patients with AD and 86 apparently healthy individuals. The disease severity was assessed using the SCORAD index; total IgE levels and complete blood count were measured, and quantification of skin microbiota was performed by real-time PCR. The results revealed a significant increase in bacterial load in the AD group compared to controls: total bacterial mass was 32 times higher, while Staphylococcus spp. and Staphylococcus aureus were 100 times higher. The concentration of Streptococcus spp. did not differ significantly. A strong positive correlation was found between the SCORAD index, total IgE level, absolute eosinophil count, and the quantity of total bacterial mass, Staphylococcus spp., and S. aureus , whereas a weak negative correlation was observed for Streptococcus spp. Patients with severe AD had significantly higher IgE levels. The obtained data confirm the central role of S. aureus and microbial dysbiosis in AD pathogenesis. The established threshold values of bacterial load (total bacterial mass > 5.0 log copies/mL, S. aureus > 4.0 log copies/mL) may serve as objective criteria for prescribing targeted antimicrobial therapy.

  • Open Access

    The role and place of dexpanthenol preparations in the prevention and treatment of atopic dermatitis, eczema, and other dermatoses in children and adults: resolution of the Expert Council of Russia

    by Margarita R. Rakhmatulina, Elena R. Araviyskaya, Olga G. Elisyutina, Larisa S. Kruglova, Olga I. Letyaeva, Gennady A. Novik, Irina O. Smirnova, Evgeny V. Sokolovskiy, Olga B. Tamrazova, Elena S. Fedenko, et al.

    The article presents the consensus opinion of experts on the role of 5% dexpanthenol preparations, particularly the original 5% dexpanthenol cream, in the comprehensive management of patients with inflammatory dermatoses such as atopic dermatitis and eczema. The material was prepared based on the results of the Expert Council held on December 17, 2025. The article reviews current concepts of the pathogenesis of these diseases with an emphasis on the central role of epidermal barrier disruption. The main approaches to restoring the skin barrier within existing therapy are described. Current clinical guidelines are analyzed and problem areas related to algorithms for the use of preparations that restore skin barrier function are identified. An overview of the evidence base for the multifaceted action of 5 % dexpanthenol, which has regenerating, anti-inflammatory, and epidermal barrier-restoring effects, is presented. The place of 5 % dexpanthenol in the treatment of atopic dermatitis is defined: as monotherapy in mild forms, and as part of combination and sequential therapy in moderate-to-severe cases. The final part of the paper formulates practical recommendations for the inclusion of dexpanthenol medicinal products in clinical algorithms for patient management.

  • Allergen-specific immunotherapy for atopic dermatitis: current status, problems and prospects

    by Valeriia S. Iuzhaninova, Olga G. Elisyutina, Evgeniy V. Smolnikov, Elena S. Fedenko, Natalya I. Ilyina, Dina V. Kleiner, Южанинова Валерия Сергеевна, Ильина Наталья Ивановна

    Atopic dermatitis is one of the most common skin diseases (accounting for 20 to 40 %) and occurs in individuals of both sexes and across different age groups. The disease can significantly reduce quality of life, including serving as a cause of social maladaptation; therefore, the issue of studying effective methods for the treatment of atopic dermatitis remains relevant, aimed at minimizing its manifestations and prolonging periods of remission. The key components of the pathogenesis of atopic dermatitis are impairment of the skin barrier function, chronic T2-inflammation, and the development of immunoglobulin E specific sensitization to allergens. Along with allergic rhinitis and bronchial asthma, atopic dermatitis belongs to T2-associated diseases, for which one of the treatment options is allergen-specific immunotherapy. This method has proven successful in the treatment of atopic diseases and, due to its disease-modifying effect, the issue of its efficacy and safety in patients with atopic dermatitis has been actively studied in recent years. This review summarizes current data on the use of allergen-specific immunotherapy with house dust mite allergens in patients with atopic dermatitis and presents a case report illustrating the successful use of allergen-specific immunotherapy with house dust mites allergen in a patient with atopic comorbidities.

  • Open Access

    Clinical efficacy and potential biomarkers of response to upadacitinib therapy in patients with severe atopic dermatitis and comorbidities

    by Evgeniy V. Smolnikov, Maria G. Byazrova, Alla O. Litovkina, Olga G. Elisyutina, Elena S. Fedenko, Бязрова Мария Георгиевна

    Atopic dermatitis is a chronic multifactorial inflammatory skin disease characterized by pruritus, a relapsing course, and characteristic morphological and topographical features that develops in genetically predisposed individuals against the background of a T2-immune response. Cytokines from T helper 2 and type 2 innate lymphoid cells — interleukins 4, 13, and 31 — play a key role in the pathogenesis of the disease, activating the JAK/STAT signaling pathways (primarily JAK1/STAT6). Despite the proven efficacy of selective Janus kinase inhibitors, including the selective Janus kinase inhibitor upadacitinib, in many inflammatory diseases, including atopic dermatitis, there remains a need to accumulate real-world clinical data, especially in patients with refractory atopic dermatitis and comorbid conditions. Aim — to evaluate the long-term efficacy, safety, and dynamics of potential biomarkers during upadacitinib therapy in patients with severe atopic dermatitis and comorbid pathology. This case series presents data from 5 adult patients (3 men, 2 women) with severe atopic dermatitis refractory to standard therapy. All patients received upadacitinib 30 mg once daily for 52 weeks. Efficacy was assessed by dynamics in Scoring Atopic Dermatitis Index, Eczema Area and Severity Index, Investigator’s Global Assessment scores, Numerical Rating Scale; Dermatology Life Quality Index. Safety was evaluated through monitoring of adverse events. Gene expression of cytokines (TARC/CCL17, MDC/CCL22, PARC/CCL18, CTACK/CCL27, eotaxin-3/CCL26, interleukins 4, 13, 17, 22, 25, 33, thymic stromal lymphopoietin) was analyzed using real-time polymerase chain reaction at baseline and at week 16 of therapy. Control over atopic dermatitis symptoms was achieved in all patients: by week 40, 100 % (5/5) of patients had achieved an Eczema Area and Severity Index 90 response, which was maintained until the end of the 52-week observation period. The median Scoring Atopic Dermatitis Index decreased from 65.3 to 2.6 by week 40, and the median Eczema Area and Severity Index score decreased from 47.6 to 0.7 by week 28. Numerical Rating Scale score decreased from 5 to 1 (median) by week 16. During the observation period, 26 mild adverse events were recorded; no serious adverse events were reported. Complete drug-induced remission was observed in one female patient with comorbid alopecia areata. No statistically significant changes were detected in the profile of the studied biomarkers. In this case series, upadacitinib demonstrated high efficacy and a favorable safety profile in patients with severe refractory atopic dermatitis over 52 weeks of therapy. The observed remission of comorbid alopecia areata expands understanding of the drug’s therapeutic potential. Larger prospective studies are needed to confirm these findings and to identify predictive biomarkers.